Some say the art of investing is the ability of catching falling knives. Pfizer Inc. (PFE, Financial) shares have sold off in 2023 and represent an attractive opportunity after having likely bottomed out.Attractive opportunity despite poor stock performance The pharmaceutical company's dividend yield of approximately 5.80% naturally draws the attention of the market and seasoned investors alike. Approximately $9 billion is spent by the company in dividend payments per year, despite a free cash flow of only ...

These high-yield dividend payers have what it takes to pump up your portfolio's passive income stream.Billionaire investors generally don't necessarily need dividend income to make ends meet. They buy dividend-paying stocks because they know that companies committed to returning a portion of earnings to shareholders tend to outperform ones that don't.In the first three months of the year, billionaire hedge fund managers bought millions of shares of Pfizer (PFE -1.78%) and AT&T (T -1.33%).Both of these divid ...

Pfizer Inc. (NYSE:PFE) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 11:20 AM ET Company Participants Albert Bourla - Chairman and CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's kick off our discussion with Pfizer here. My name is Chris Shibutani. I'm a member of the Goldman Sachs Healthcare Research Team. Thank you so much to everybody here for joining us for this conference and for this discussion. Super pleased to have Albert Bourla, CE ...

Massimo Giachetti My thesis Pfizer (NYSE:PFE) was one of few pharmaceutical companies which were able to develop the COVID-19 vaccine within a short period, and I was very surprised to find out that the stock currently trades below pre-pandemic levels. Data by YCharts The business looks solid as the revenue mix is diverse across various geographies, diseases and products. Despite recent dip in profitability, it is still stellar and enables the company to pour billions per annum in developing new products. T ...

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. ...

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. ...

Pfizer's list of patent-protected medicines is growing by leaps and bounds, but its stock price is under pressure.Pfizer (PFE 2.27%) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.Shares of Pfizer have been beaten severely in response to sinking sales of Comirnaty, its COVID-19 vaccine, and Paxlovid, an antiviral treatment. At its beaten-down price, it offers an eye-popping 5.9% dividend yield.Pfizer has ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago.I plan on writing up some data, along with a wrap-up or two after the conference, so stay tuned for my coverage. If you see me at ASCO this weekend, don't hesitate to say hello!I'll be focusing on some of the larger names in the industry. Here's some of the data I'm looking at:More than 5,000 research abstracts will be presented or published at ASCO, which starts on Friday and lasts until Tuesday. There w ...

The major market indexes keep hitting new highs, but these stocks haven't participated in the bull run.Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before buying any stocks these days.The benchmark index is way up, but not all of its components have participated in the rally. Shares of Pfizer (PFE 0.66%) and Walgreens Boots Alliance (WBA 0.50%) have been beaten down m ...